The 20 references in paper G. Orlova P., E. Surkova A., S. Lapin V., Г. Орлова П., Е. Суркова А., С. Лапин В. (2016) “Маркеры активности экзогенных интерстициальных заболеваний легких // Extrinsic interstitial lung disease activity markers” / spz:neicon:pulmonology:y:2016:i:2:p:180-185

1
Илькович М.М. Терминология и классификация. В кн.: М.М. Илькович, ред. Диссеминированные заболевания легких. М.: ГЭОТАР-Медиа; 2011: 10–13. / Il'kovich M.M. Terminology and characterization. In: M.M.Il'kovich, ed. Disseminated lung diseases. Moscow: GEOTAR-Media; 2011: 10–13 (in Russian).
(check this in PDF content)
2
Kinnula V.L., Ishikawa N., Bergmann U. et al. Proteomic approaches for studying human parenchymal lung diseases. Exp. Rev. Proteomics. 2009; l (6): 619–629.
(check this in PDF content)
3
Nukiwa T. The role of biomarkers in management of interstitial lung disease: implication of biomarkers derived from type II pneumocytes. In: Du Bois R.M., Richeldi L., eds. Interstitial Lung Disease. Eur. Respir. Mon. UK.: ERS Journals Ltd; 2009, 46: 47–66.
(check this in PDF content)
4
Hesselstrand R., Wildt M., Bozovic G. et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir. Med. 2013; 107 (7): 1079–1086.
(check this in PDF content)
5
Xu L., Yan D.R., Zhu S.L. et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur. Rev. Med. Pharmacol. Sci. 2013; 17 (22): 3073–3077.
(check this in PDF content)
6
Fazlyeva R.M., Mavziutova G.A., Kuzovkina O.Z. Clinical and diagnostic value of the determination of alveomucin in patients with community-acquired pneumonia. Klin. Lab. Diagn. 2010; 3: 51–53.
(check this in PDF content)
7
Zheng D., Limmon G.V., Yin L. et al. A cellular pathway involved in Clara cell to alveolar type II cell differentiation after severe lung injury.PLoS One.2013; 8 (8): e71028.
(check this in PDF content)
8
Kropski J., Fremont R., Calfee C., Ware L. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009; 135 (6): 1440–1447.
(check this in PDF content)
9
Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.Respir. Invest.2012; 50 (1): 3–13.
(check this in PDF content)
10
Ichiyasu H., Ichikado K., Yamashita A. et al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in non-specific interstitial pneumonia. Respiration. 2012; 83: 190–197.
(check this in PDF content)
11
Ley B., Brown K., Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis.Am. J. Physiol. Lung Cell. Mol. Physiol.2014; 307: L681–L691.
(check this in PDF content)
12
Takahashi T., Munakata M., Ohtsuka Y. et al. Serum KL-6 concentrations in dairy farmers. Chest. 2000; 118: 445–450.
(check this in PDF content)
13
Ohnishi H., Miyamoto S., Kawase S. et al. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis. BMC Pulm. Med.2014; 7 (14): 129. DOI: 10.1186/1471-2466-14-129.
(check this in PDF content)
14
Kawase S., Hattori N., Ishikawa N. et al. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced inter Bronchiolar Clara cells play a critical role in lung homoeostasis interstitial lung disease. Respir. Res. 2011; 12: 97. http://respiratory%research. com/content/12/1/97
(check this in PDF content)
15
Ohnishi H., Yokoyama A., Yasuhara Y. et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003; 58: 872–875.
(check this in PDF content)
16
Doishita S., Inokuma S., Asashima H. et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern. Med.2011; 50 (23): 2889–2892.
(check this in PDF content)
17
Petrek M., Hermans C., Kolek V. et al. Clara cell protein (CC16) in serum and bronchoalveolar lavage fluid of subjects exposed to asbestos. Biomarkers. 2002; 7 (1): 58–67.
(check this in PDF content)
18
Wang S.X., Liu P., Wei M.T. et al. Roles of serum Сlara cell protein 16 and surfactant protein-D in the early diagnosis and progression of silicosis.J. Occup. Environ. Med.2007; 49 (8): 834–839.
(check this in PDF content)
19
HałatekT., Trzcinka-Ochocka M., Matczak W., Gruchała J. Serum Clara cell protein as an indicator of pulmonary impairment in occupational exposure at aluminum foundry. Int. J. Occup. Med. Environ. Health.2006; 19 (4): 211–223.
(check this in PDF content)
20
Quintar A.A., Leimgruber C., García L. et al. Restoration of the normal Clara cell phenotype after chronic allergic inflammation. Int. J. Exp. Pathol. 2013; 94 (6): 399–411. Поступила 05.02.16 УДК 616.246092
(check this in PDF content)